1
|
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
|
Clin Infect Dis
|
2007
|
5.15
|
2
|
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
|
J Clin Oncol
|
2013
|
4.50
|
3
|
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
|
J Clin Oncol
|
2011
|
3.09
|
4
|
Inhibitory effect of tumor cell-derived lactic acid on human T cells.
|
Blood
|
2007
|
2.64
|
5
|
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
|
J Clin Oncol
|
2011
|
1.84
|
6
|
Species-specific regulation of Toll-like receptor 3 genes in men and mice.
|
J Biol Chem
|
2003
|
1.73
|
7
|
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
|
J Clin Oncol
|
2013
|
1.60
|
8
|
Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation.
|
J Biol Chem
|
2003
|
1.39
|
9
|
Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.
|
Haematologica
|
2008
|
1.24
|
10
|
Active DNA demethylation in human postmitotic cells correlates with activating histone modifications, but not transcription levels.
|
Genome Biol
|
2010
|
1.20
|
11
|
Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
|
J Immunother
|
2006
|
1.17
|
12
|
CCAAT enhancer-binding protein beta regulates constitutive gene expression during late stages of monocyte to macrophage differentiation.
|
J Biol Chem
|
2007
|
0.99
|
13
|
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.
|
Ann Hematol
|
2013
|
0.98
|
14
|
Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma.
|
Cancer
|
2004
|
0.97
|
15
|
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.
|
Haematologica
|
2013
|
0.94
|
16
|
Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies.
|
J Antimicrob Chemother
|
2012
|
0.92
|
17
|
Transcription factor Tfec contributes to the IL-4-inducible expression of a small group of genes in mouse macrophages including the granulocyte colony-stimulating factor receptor.
|
J Immunol
|
2005
|
0.92
|
18
|
Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
|
J Immunol
|
2003
|
0.91
|
19
|
Analysis of the immune response against tetanus toxoid: enumeration of specific T helper cells by the Elispot assay.
|
Immunobiology
|
2002
|
0.90
|
20
|
Monocyte-derived human macrophages mediate anergy in allogeneic T cells and induce regulatory T cells.
|
J Immunol
|
2006
|
0.87
|
21
|
Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia.
|
Leuk Lymphoma
|
2011
|
0.87
|
22
|
Elimination of activated but not resting primary human CD4+ and CD8+ T cells by Fas ligand (FasL/CD95L)-expressing Killer-dendritic cells.
|
Immunobiology
|
2004
|
0.86
|
23
|
Comparison of automated differential blood cell counts from Abbott Sapphire, Siemens Advia 120, Beckman Coulter DxH 800, and Sysmex XE-2100 in normal and pathologic samples.
|
Am J Clin Pathol
|
2013
|
0.86
|
24
|
Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples.
|
Eur J Haematol
|
2012
|
0.85
|
25
|
Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group.
|
J Clin Oncol
|
2013
|
0.84
|
26
|
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
|
Leuk Lymphoma
|
2010
|
0.82
|
27
|
Measurement of immature platelets with Abbott CD-Sapphire and Sysmex XE-5000 in haematology and oncology patients.
|
Clin Chem Lab Med
|
2013
|
0.81
|
28
|
Genomic organization of the human gene HEP27: alternative promoter usage in HepG2 cells and monocyte-derived dendritic cells.
|
Genomics
|
2002
|
0.81
|
29
|
Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.
|
Ann Hematol
|
2014
|
0.81
|
30
|
Characterization of cells prepared by dendritic cell-tumor cell fusion.
|
Cancer Immun
|
2002
|
0.80
|
31
|
Structure of the human carboxypeptidase M gene. Identification of a proximal GC-rich promoter and a unique distal promoter that consists of repetitive elements.
|
Gene
|
2002
|
0.79
|
32
|
Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study.
|
J Immunother
|
2004
|
0.79
|
33
|
The JAM-assay: optimized conditions to determine death-receptor-mediated apoptosis.
|
Methods
|
2003
|
0.79
|
34
|
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
|
Ann Hematol
|
2014
|
0.78
|
35
|
Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.
|
J Antimicrob Chemother
|
2007
|
0.77
|
36
|
Imatinib in chronic myeloid leukemia.
|
N Engl J Med
|
2007
|
0.76
|
37
|
[Workshop - economic governance mechanisms : for Hematology and Oncology].
|
Oncol Res Treat
|
2015
|
0.75
|
38
|
Prophylactic application of nebulized liposomal amphotericin B in hematologic patients with neutropenia.
|
Onkologie
|
2011
|
0.75
|
39
|
Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial.
|
Ann Hematol
|
2014
|
0.75
|
40
|
Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide.
|
Ann Hematol
|
2007
|
0.75
|